Soluble transforming growth factor-beta type II receptor inhibits negativeremodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth
Jd. Smith et al., Soluble transforming growth factor-beta type II receptor inhibits negativeremodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth, CIRCUL RES, 84(10), 1999, pp. 1212-1222
Using the rat balloon catheter denudation model, we examined the role of tr
ansforming growth factor-beta (TGF-beta) isoforms in vascular repair proces
ses. By en face in situ hybridization, proliferating and quiescent smooth m
uscle cells in denuded vessels expressed high levels of mRNA for TGF-beta(1
), TGF-alpha(2), TGF-beta(3), and lower levels of TGF-beta receptor II (TGF
-beta RII) mRNA. Compared with normal endothelium, TGF-beta(1) and TGF-beta
(2) as well as TGF-beta RII, mRNA were upregulated in endothelium at the wo
und edge. Injected recombinant soluble TGF-beta RII (TGF-beta R:Fc) localiz
ed preferentially to the adventitia and developing neointima in the injured
carotid artery, causing a reduction in intimal lesion formation (up to 65%
) and an increase in lumen area (up to 88%). The gain in lumen area was lar
gely due to inhibition of negative remodeling, which coincided with reduced
adventitial fibrosis and collagen deposition. Four days after injury, TGF-
beta R:Fc treatment almost completely inhibited the induction of smooth mus
cle alpha-actin expression in adventitial cells. In the vessel wall, TGF-be
ta R:Fc caused a marked reduction in mRNA levels for collagens type I and I
II. TGF-beta R:Fc had no effect on endothelial proliferation as determined
by reendothelialization of the denuded rat aorta. Together, these findings
identify the TGF-beta isoforms as major factors mediating adventitial fibro
sis and negative remodeling after vascular injury, a major cause of resteno
sis after angioplasty.